gms | German Medical Science

73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

29.05. - 01.06.2022, Köln

Death receptor 6 as prognostic marker in low grade glioma

Death Receptor 6 als prognostischer Marker in LGG

Meeting Abstract

Suche in Medline nach

  • Sarah Stegmann - Universitätsklinikum Köln, Klinik für Neurochirurgie, Köln, Deutschland
  • Roland Goldbrunner - Universitätsklinikum Köln, Klinik für Neurochirurgie, Köln, Deutschland
  • presenting/speaker Marco Timmer - Universitätsklinikum Köln, Klinik für Neurochirurgie, Köln, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie. Köln, 29.05.-01.06.2022. Düsseldorf: German Medical Science GMS Publishing House; 2022. DocV181

doi: 10.3205/22dgnc175, urn:nbn:de:0183-22dgnc1753

Veröffentlicht: 25. Mai 2022

© 2022 Stegmann et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Objective: Low grade glioma (LGG) are heterogenous tumours, causing variable survival in patients. Identifying molecular markers for a more accurate prognosis is therefore important. Since death receptor 6 (DR6) is upregulated in glioma and shows an aberrant signalling network, we tested its suitability as prognostic marker.

Methods: DR6 was investigated in patient samples via PCR and Western Blot. Clinical data was analysed and compared to The Cancer Genome Atlas (TCGA) “brain lower grade glioma” dataset.

Results: DR6 is enhanced in LGG and its expression increases in recurrent LGG. DR6 mRNA expression was enhanced in tumour samples (0.2418 ± 0.1762 vs. 0.08442 ± 0.02662, p=0.0031). On the protein level, the receptor was increased in cancer samples, though not significantly (0.2634 ± 0.1187 vs. 0.1688 ± 0.1083). The receptor shows a protective effect in primary LGG with a significantly elongated progression free survival that was confirmed in the TCGA study. This effect is reversed in relapsed LGG in which cases with high DR6 expression reveal a shorter overall survival. We analysed only the primary LGG tumour samples in our study which exhibited a significantly longer PFS for cases with high DR6 expression compared to samples with low DR6 level (HR 0.4094, 95% CI 0.1968 to 0.8516) (Figure 4c). This effect was independent of other prognostic factors.

Conclusion: DR6 is an interesting candidate for further studies regarding its effect as a prognostic marker, playing an opposing role in primary and relapsed LGG.